213 related articles for article (PubMed ID: 35362863)
1. Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer.
Simmons D; Blank SV; ElNaggar AC; Chastek B; Bunner SH; McLaurin K
Adv Ther; 2022 Jun; 39(6):2544-2561. PubMed ID: 35362863
[TBL] [Abstract][Full Text] [Related]
2. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
3. Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
Liu J; Hawkes C; Walder L; Spalding C; Travers K; Maiese EM; Hurteau J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1377-1387. PubMed ID: 34595950
[No Abstract] [Full Text] [Related]
4. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
5. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
6. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
9. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization for chronic low back pain among high-utilizers.
Kirsch EP; Yang LZ; Lee HJ; Parente B; Lad SP
Spine J; 2024 Apr; 24(4):601-616. PubMed ID: 38081464
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder.
Jain R; Laliberté F; Germain G; Mahendran M; Higa S; Harrington A; Parikh M
J Manag Care Spec Pharm; 2023 Aug; 29(8):896-906. PubMed ID: 37523314
[No Abstract] [Full Text] [Related]
14. Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Chase DM; Annavarapu S; Tseng WY; Shi J; Szamreta E; Monberg M
Gynecol Oncol; 2024 Jan; 180():79-85. PubMed ID: 38056115
[TBL] [Abstract][Full Text] [Related]
15. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
16. Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis.
Gitlin M; McGarvey N; Shivaprakash N; Cong Z
J Manag Care Spec Pharm; 2023 Jun; 29(6):659-670. PubMed ID: 37276034
[No Abstract] [Full Text] [Related]
17. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.
Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
[TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
20. Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics.
DeClue RW; Szamreta EA; Gautam S; Fisher MD; Monberg MJ
Future Oncol; 2023 May; 19(16):1113-1124. PubMed ID: 37170823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
